Abstract: The invention provides isolated protein kinase polypeptides related to novel brain-localized protein kinases homologous to known homeodomain-interacting protein kinases (HIPKs), isolated nucleic acid molecules that encode these polypeptides, inhibitors, and methods related thereto. The novel polypeptides and nucleic acid molecules of the invention are termed HIPK4. The invention also provides genetically engineered expression vectors, host cells, and transgenic animals comprising the novel nucleic acid molecules of the invention. The invention additionally provides antisense and RNAi molecules to the nucleic acid molecules of the invention, as well as inhibitors, activators, and antibodies capable of binding to the protein kinase polypeptides of the invention. The invention further provides uses of HIPK4 and its inhibitors, e.g., mutants of HIPK4 lacking protein kinase activity, for modulation of apoptosis, as well as the prevention and treatment of neurological disorders and cancers.

Abstract: This invention provides compositions, organisms and methodologies employing a novel human protein kinase, HPK3P23. The novel human kinase has sequence homology to the catalytic domains of several protein kinases. The gene encoding this novel protein kinase is localized in or near the 3p23 locus of the human chromosome 3. The sequence similarity between the novel human protein and the catalytic domain of protein kinases indicates that the novel human protein may function as a protein kinase.

Abstract: This invention provides compositions, organisms and methodologies employing a novel human gene encoding a protein that has sequence homology to a consensus sequence of calcineurin-like phosphoesterase family are disclosed. The novel protein is encoded by a human gene comprising 4 exons. The human gene is localized in the 10p15 locus of human chromosome 10. The sequence similarities between the novel human protein and the consensus sequence of calcineurin-like phosphoesterases indicate that the novel human protein may function as a calcineurin-like protein phosphatase.

Abstract: This invention provides compositions, organisms and methodologies employing a novel human protein kinase, MCRK1. The novel human kinase has sequence homology to rat myotonic dystrophy kinase-related Cdc42 binding kinase (MRCK) alpha. The gene encoding the novel kinase is localized in locus 11q13 of human chromosome 11. The novel protein kinase comprises multiple functional/structural domains that include a kinase domain, a pkinase_C domain, a DAG-PE binding domain, and a CNH domain. The sequence and structure similarity between the novel human protein and rat MRCK alpha indicates that the novel human protein may function as a downstream effector of Cdc42 in cytoskeleton reorganization.

Abstract: This invention provides compositions, organisms and methodologies employing a novel human protein kinase, MCRK1. The novel human kinase has sequence homology to rat myotonic dystrophy kinase-related Cdc42 binding kinase (MRCK) alpha. The gene encoding the novel kinase is localized in locus 11q13 of human chromosome 11. The novel protein kinase comprises multiple functional/structural domains that include a kinase domain, a pkinase_C domain, a DAG-PE binding domain, and a CNH domain. The sequence and structure similarity between the novel human protein and rat MRCK alpha indicates that the novel human protein may function as a downstream effector of Cdc42 in cytoskeleton reorganization.

Abstract: The invention provides isolated protein kinase polypeptides related to novel brain-localized protein kinases homologous to known homeodomain-interacting protein kinases (HIPKs), and the isolated nucleic acid molecules that encode these polypeptides. The novel polypeptides and nucleic acid molecules of the invention are termed HIPK4. The invention also provides genetically engineered expression vectors, host cells, and transgenic animals comprising the novel nucleic acid molecules of the invention. The invention additionally provides antisense and RNAi molecules to the nucleic acid molecules of the invention. The invention further provides inhibitors, activators, and antibodies capable of binding to the protein kinase polypeptides of the invention, and their use in the prevention and treatment of neurological disorders.

Abstract: This invention provides compositions, organisms and methodologies employing a novel human gene encoding a protein that has sequence homology to a consensus sequence of calcineurin-like phosphoesterase family are disclosed. The novel protein is encoded by a human gene comprising 4 exons. The human gene is localized in the 10p15 locus of human chromosome 10. The sequence similarities between the novel human protein and the consensus sequence of calcineurin-like phosphoesterases indicate that the novel human protein may function as a calcineurin-like protein phosphatase.

Abstract: This invention provides compositions, organisms and methodologies employing a novel human protein kinase, HPK3P23. The novel human kinase has sequence homology to the catalytic domains of several protein kinases. The gene encoding this novel protein kinase is localized in or near the 3p23 locus of the human chromosome 3. The sequence similarity between the novel human protein and the catalytic domain of protein kinases indicates that the novel human protein may function as a protein kinase.

Abstract: Disclosed herein are nucleic acid and polypeptide sequences of the mouse and rat homologues of human cysteine-rich secretory protein-1. Also disclosed herein are methods related to the use of the aforementioned mouse and rat homologues.

Abstract: This invention provides compositions, organisms and methodologies employing a novel human protein kinase, HPK3P23. The novel human kinase has sequence homology to the catalytic domains of several protein kinases. The gene encoding this novel protein kinase is localized in or near the 3p23 locus of the human chromosome 3. The sequence similarity between the novel human protein and the catalytic domain of protein kinases indicates that the novel human protein may function as a protein kinase.

Abstract: This invention provides compositions, organisms and methodologies employing a novel human protein kinase, MCRK2. The novel human kinase has sequence homology to rat myotonic dystrophy kinase-related Cdc42 binding kinase (MRCK) alpha. The gene encoding the novel kinase is localized in locus 1q42 of human chromosome 1. The novel protein kinase comprises multiple functional/structural domains that include a kinase domain, a pkinase_C domain, a DAG-PE binding domain, and a CNH domain. The sequence and structure similarity between the novel human protein and rat MRCK alpha indicates that the novel human protein may function as a downstream effector of Cdc42 in cytoskeleton reorganization.

Abstract: The invention provides isolated protein kinase polypeptides homologous to Kinase Suppressor of Ras (KSR), and the isolated nucleic acid molecules that encode these polypeptides. The novel polypeptides and nucleic acid molecules of the invention are termed KSR-2. The invention also provides genetically engineered expression vectors, host cells, and transgenic animals comprising the novel nucleic acid molecules of the invention. The invention additionally provides antisense and RNAi molecules to the nucleic acid molecules of the invention. The invention further provides inhibitors, activators, and antibodies capable of binding to the protein kinase polypeptides of the invention. The invention also provides for the regulation of Cot/Tp12-mediated cellular functions, such as ERK and NF-&kgr;B activation, as well as IL-8 production, through the use of the nucleic acid and protein kinase polypeptide molecules of the invention.

Abstract: The invention provides isolated protein kinase polypeptides related to novel brain-localized protein kinases homologous to known homeodomain-interacting protein kinases (HIPKs), and the isolated nucleic acid molecules that encode these polypeptides. The novel polypeptides and nucleic acid molecules of the invention are termed HIPK4. The invention also provides genetically engineered expression vectors, host cells, and transgenic animals comprising the novel nucleic acid molecules of the invention. The invention additionally provides antisense and RNAi molecules to the nucleic acid molecules of the invention. The invention further provides inhibitors, activators, and antibodies capable of binding to the protein kinase polypeptides of the invention, and their use in the prevention and treatment of neurological disorders.

Abstract: This invention provides compositions, organisms and methodologies employing a novel human protein kinase, MCRK1. The novel human kinase has sequence homology to rat myotonic dystrophy kinase-related Cdc42 binding kinase (MRCK) alpha. The gene encoding the novel kinase is localized in locus 11q13 of human chromosome 11. The novel protein kinase comprises multiple functional/structural domains that include a kinase domain, a pkinase_C domain, a DAG-PE binding domain, and a CNH domain. The sequence and structure similarity between the novel human protein and rat MRCK alpha indicates that the novel human protein may function as a downstream effector of Cdc42 in cytoskeleton reorganization.

Abstract: This invention provides compositions, organisms and methodologies employing a novel human protein kinase, HPK3P23. The novel human kinase has sequence homology to the catalytic domains of several protein kinases. The gene encoding this novel protein kinase is localized in or near the 3p23 locus of the human chromosome 3. The sequence similarity between the novel human protein and the catalytic domain of protein kinases indicates that the novel human protein may function as a protein kinase.

Abstract: This invention provides compositions, organisms and methodologies employing a novel human protein kinase, NRHK1. The novel protein kinase is encoded by a human gene comprising 21 exons. The human gene is localized in or near the 9q34 locus of human chromosome 9. The sequence similarity between the novel human protein and the consensus sequence of NIMA-related kinase indicates that the novel human protein may function as an NIMA-related kinase.

Abstract: This invention provides compositions, organisms and methodologies employing a novel human gene encoding a protein that has sequence homology to a consensus sequence of calcineurin-like phosphoesterase family are disclosed. The novel protein is encoded by a human gene comprising 4 exons. The human gene is localized in the 10p15 locus of human chromosome 10. The sequence similarities between the novel human protein and the consensus sequence of calcineurin-like phosphoesterases indicate that the novel human protein may function as a calcineurin-like protein phosphatase.